DIABETIC RETINOPATHY AND CLUSTERS OF METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (58-63)

Список литературы: 1. Arterialna hipertenziya. Onovlena ta adaptovana klinichna nastanova, zasnovana na dokazakh. Dodatok do Nakazu MOZ Ukrayiny № 384 vid 24.05.2012 “Pro zatverdzhennya ta vprovadzhennya medyko-tekhnolohichnykh dokumentiv zi standartyzatsiyi medychnoyi dopomohy pry arterialniy hipertenziyi” [Arterial Hypertension. Updated and Adapted Evidence-Based Clinical Recommendation. Supplement to the Order of the Ministry of Health of Ukraine # 384 as of May 24, 2012 “On Approval and Implementation of Medical and Technological Documents on Standardization of Medical Assistance for Hypertension”] — www.moz.gov.ua/ua/portal/dn_20120524_384.html. 2. Bodanova A.A., Mkrtumyan A.M., Davydov A.L. et al. Struktura pozdnikh sosudistykh oslozhneniy pri vpervyye vyyavlennom sakharnom diabete 2 tipa // Sakharnyy diabet. — 2006. — T. 9, № 4. — S. 35-37. [Bodanova A.A., Mkrtumyan A.M., Davydov A.L. et al. The structure of late vascular complications in firstly diagnosed type 2 diabetes mellitus // Diabetes mellitus. - 2006. - V. 9, # 4. - P. 35-37.] — DOI: http://dx.doi.org/10.14341/2072-0351-6187. 3. Guseynova R.R., Mirzazade V.A. Vliyaniye dlitelnosti sakharnogo diabeta na rasprostranennost diabeticheskoy retinopatii u bolnykh sakharnym diabetom 2 tipa s metabolicheskim sindromom // Sakharnyy diabet. — 2010. — T. 13, № 2. — S. 94-96. [Huseynova R.R., Mirzazade V.A. The influence of the duration of diabetes on the development of diabetic retinopathy in patients with type 2 diabetes mellitus with metabolic syndrome // Diabetes mellitus. - 2010. - V. 13, # 2. - P. 94-96.] — DOI: http://dx.doi.org/10.14341/2072-0351-5682. 4. Kirilyuk M.L. Medikamentoznoye lecheniye i profilaktika diabeticheskoy retinopatii pri sakharnom diabete 1 tipa // Mizhnarodniy yendokrinologichniy zhurnal. — 2012. — № 5(45). — S. 70-75. [Kirilyuk M.L. Drug treatment and prevention of diabetic retinopathy in type 1 diabetes mellitus // International Endocrinology Journal. - 2012. - # 5 (45). - P. 70-75. 5. Kyrylyuk M.L., Kostyev F.I., Pidayev A.V., et al. Biometrychni ta biokhimichni pokaznyky metabolichnoho syndromu abo ryzyku yoho vynyknennya u khvorykh iz dobroyakisnoyu hiperplaziyeyu peredmikhurovoyi zalozy // Klinichna endokrynolohiya i endokrynna khirurhiya. — 2012. — № 3(40). — S. 53-58. [Kirilyuk M.L., Kostiev F.I., Pidaev A.V., Shatalyuk S.S. Biometric and biochemical indicators of metabolic syndrome or risk of its occurrence in patients with benign prostatic hyperplasia // Clinical endocrinology and endocrine surgery. - 2012. - # 3 (40). - P. 53-58]. 6. Sirenko Y.M. Tsilovyy riven AT pry tsukrovomu diabeti 2-ho typu: otsinka naukovykh dokaziv // Mizhnarodnyy endokrynolohichnyy zhurnal. — 2012. — № 6(46). — S. 10-14. [Sirenko Y.M. Targeted blood pressure level in type 2 diabetes mellitus: evaluation of scientific evidence // International Endocrinology Journal. - 2012. - # 6 (46). - P. 10-14]. 7. Shestakova M.V. Rol tkanevoy reninangiotenzin-aldosteronovoy sistemy v razvitii metabolicheskogo sindroma, sakharnogo diabeta i yego sosudistykh oslozhneniy // Sakharnyy diabet. — 2010. — T. 13, № 3. — S. 14-19. [Shestakova M.V. The role of tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and its vascular complications // Diabetes mellitus. - 2010. - V. 13, # 3. - P. 14-19.] — DOI: http://dx.doi.org/10.14341/2072-0351-5481. 8. Catapano A.L., Graham I., de Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias // European Heart Journal. — 2016. — Vol. 37, Issue 39. — P. 2999-3058. — doi:10.1093/eurheartj/ehw272. 9. Chase H.P., Garg S.K., Jackson W.E. et al. Blood pressure and retinopathy in type 1 diabetes // Ophtalmology. — 1990. — № 97. — P. 155-159. 10. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice // Eur. Heart J. — 2012. — Vol. 33(13). — P. 1635-1701. 11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA. — 2001. — Vol. 285. — Р. 24862497. 12. Glantz S.A. Primer of biostatistics. 4th Edition. — McGraw-Hill, New York, St. Louis, SanFrancisco, Madrid, Milan, Sydney, Tokyo, Toronto; 1994. 13. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and Management of the Metabolic Syndrome // Circulation. — 2005. — Vol. 112. — P. 2735-2752. — http://dx.doi.org/10.1161/CIRCULATIONAHA.105.1 69404. 14. Klein R., Klein B.E.K., Moss S.E. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes // Ophtalmology. — 1998. — Vol. 105. — P. 1801-1805. 15. Kohner E.M., Porta M. Screening for diabetic retinopathy in Europe: A field handbook. — Boehringer Mannheim, Italy, 1992. 16. Testa M.A., Puklin J.E., Sherwin R.S. et al. Clinical predictors of retinopathy and its progression in patients with type 1 diabetes during CSII and conventional insulin treatment // Diabetes. — 1985. — Vol. 34(Suppl. 3). — P. 61-68. 17. The metabolic syndrome and cardiovascular disease mortality in middle-aged men / H.-M. Lakka, D.E. Laaksonen, T.A. Lakka [et al.] // JAMA. — 2002. — Vol. 283. — P. 2909-2916.